These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30237154)

  • 1. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
    Driessen C; Müller R; Novak U; Cantoni N; Betticher D; Mach N; Rüfer A; Mey U; Samaras P; Ribi K; Besse L; Besse A; Berset C; Rondeau S; Hawle H; Hitz F; Pabst T; Zander T
    Blood; 2018 Nov; 132(19):2097-2100. PubMed ID: 30237154
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
    Hitz F; Kraus M; Pabst T; Hess D; Besse L; Silzle T; Novak U; Seipel K; Rondeau S; Stüdeli S; Vilei SB; Samaras P; Mey U; Driessen C;
    Blood Cancer J; 2019 Aug; 9(9):70. PubMed ID: 31455773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients.
    Zhang L; Mager DE
    J Pharm Sci; 2019 Jan; 108(1):732-740. PubMed ID: 30472266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
    Maeno S; Koh S; Ichii M; Oie Y; Nishida K; Kanakura Y
    Ann Hematol; 2019 Mar; 98(3):793-795. PubMed ID: 30645676
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
    Ludwig H; Weisel K; Petrucci MT; Leleu X; Cafro AM; Garderet L; Leitgeb C; Foa R; Greil R; Yakoub-Agha I; Zboralski D; Vauléon S; Dümmler T; Beyer D; Kruschinski A; Riecke K; Baumann M; Engelhardt M
    Leukemia; 2017 Apr; 31(4):997-1000. PubMed ID: 28074071
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A
    Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
    Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
    Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
    Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
    [No Abstract]   [Full Text] [Related]  

  • 13. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.
    Krečak I; Ruščić I; Zlatović JJ; Šupe M; Krečak MV; Gverić-Krečak V
    Ann Hematol; 2021 Jun; 100(6):1623-1624. PubMed ID: 33404692
    [No Abstract]   [Full Text] [Related]  

  • 14. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Alodhaibi I; Ailawadhi S; Burbano GP; O'Brien PJ; Buadi FK; Hayman S; Kumar SK; Gonsalves WI
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):298-304. PubMed ID: 38220589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
    Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
    Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
    Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
    Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
    [No Abstract]   [Full Text] [Related]  

  • 17. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
    Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
    Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
    [No Abstract]   [Full Text] [Related]  

  • 18. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
    Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
    Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
    Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.